Business news and discussion on TalkFuse.
British Business Bank ‘throws kitchen sink’ at life sciences to address dearth of UK investment
The British Business Bank has increased its backing for UK life sciences to £1.1bn, aiming to help domestic companies grow and attract more pension-fund investment. Its chief investment officer says financing the sector requires a broad effort, as specialist firms need larger pools of capital to scale in Britain.
The backing includes £832m across 20 life sciences funds and £302m for domestic scale-ups, including £25m for Alchemab Therapeutics and £15m for T-Therapeutics. Pension funds signed up to the Mansion House Accord have pledged to put 5% of assets into private markets by 2030, but 70% of £11.1bn committed so far has gone to property and only £500m to private equity. The bank has also committed €58m to a European fund, while sector leaders point to overseas acquisitions and limited research facilities as challenges for UK growth.
In short
- The bank’s life sciences backing has reached £1.1bn.
- Pension investment in private markets has largely gone to property.
- The bank is also courting European funds to back UK firms.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
The bank’s broader investment could help promising UK life-sciences firms reach the scale needed to develop treatments and compete globally, while making it easier for pension funds to invest in the sector. Building domestic capital and research capacity may also help keep valuable companies, expertise and future economic benefits in Britain.
The case against
Public backing on this scale may expose taxpayers to the risks of a sector where development is costly and uncertain, and could steer capital towards life sciences at the expense of other priorities. Investment alone may not solve the deeper constraints described, including limited research facilities and the tendency for successful firms to be acquired overseas; pension funds may reasonably favour assets they judge more suitable for their members.
Explained simply
Life sciences includes businesses developing medicines, medical technologies and treatments. Many start as research-led companies, but bringing a discovery to market and expanding a business can take years and require substantial investment.
The British Business Bank is a state-owned institution that invests in businesses and funds to support growth in the UK. In life sciences, it backs specialist investment funds as well as companies seeking money to expand; Alchemab Therapeutics and T-Therapeutics are among the businesses it has supported.
Pension funds manage savings paid in by workers and employers, and can invest some of that money in private companies through private-market funds. The amount directed to life sciences matters because UK firms may need substantial funding and research facilities to grow at home, while overseas buyers can acquire promising businesses.